{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:31:15Z","timestamp":1759883475711,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.humpath.2025.105933","type":"journal-article","created":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:22:15Z","timestamp":1757254935000},"page":"105933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Leukemic phase of MYC\/BCL2 double-hit high-grade B-cell lymphoma: A report of 35 cases"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-8006","authenticated-orcid":false,"given":"L. Jeffrey","family":"Medeiros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.humpath.2025.105933_bib1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.humpath.2025.105933_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100441","article-title":"Fifth edition of the world health classification of tumors of the hematopoietic and lymphoid tissues: B-cell neoplasms","volume":"37","author":"Medeiros","year":"2024","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2025.105933_bib3","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.1999.17.5.1558","article-title":"Small noncleaved, non-Burkitt's (Burkit-like) lymphoma: cytogenetics predict outcome and reflect clinical presentation","volume":"17","author":"Macpherson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105933_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/modpathol.3800500","article-title":"Lymphoid neoplasms associated with concurrent t(14;18) and 8q24\/c-MYC translocation generally have a poor prognosis","volume":"19","author":"Kanungo","year":"2006","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.humpath.2025.105933_bib5","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.humpath.2025.105933_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11864-015-0374-0","article-title":"Aggressive B cell lymphoma: optimal therapy for MYC-positive, double-hit, and triple-hit DLBCL","volume":"16","author":"Dunleavy","year":"2015","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"10.1016\/j.humpath.2025.105933_bib7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood-2016-02-636316","article-title":"Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 And\/Or BCL6 rearrangements","volume":"129","author":"Sesques","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2025.105933_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1188478","article-title":"Induction treatment in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and\/or BCL6 rearrangement: a systematic review and meta-analysis","volume":"13","author":"Zeremski","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.humpath.2025.105933_bib9","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bbmt.2017.11.023","article-title":"Outcomes after allogeneic stem cell transplantation in patients with double-hit and double-expressor lymphoma","volume":"24","author":"Herrera","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.humpath.2025.105933_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/modpathol.2011.147","article-title":"B-cell lymphomas with MYC\/8q24 rearrangements and IGH@BCL2\/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome","volume":"25","author":"Li","year":"2012","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.humpath.2025.105933_bib11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.humpath.2025.105933_bib12","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.humpath.2025.105933_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clml.2015.11.012","article-title":"Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) with or without rituximab as first-line therapy for aggressive non-Hodgkin lymphoma","volume":"16","author":"Lamar","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.humpath.2025.105933_bib14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/hon.2975","article-title":"Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: a single-center, retrospective, cohort study","volume":"40","author":"Wang","year":"2022","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1016\/j.humpath.2025.105933_bib15","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood-2015-11-683730","article-title":"MYC\/BCL2 double-hit lymphoma\/leukemia mimicking acute leukemia at initial presentation","volume":"127","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.humpath.2025.105933_bib16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/blood.2024027114","article-title":"CD5-positive high-grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements","volume":"145","author":"Wang","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.humpath.2025.105933_bib17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/modpathol.2014.95","article-title":"B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC\/BCL2 double-hit lymphomas","volume":"28","author":"Li","year":"2015","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2025.105933_bib18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/ejh.13384","article-title":"MYC rearrangement and MYC\/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma","volume":"104","author":"Xu","year":"2020","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105933_bib19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.humpath.2025.105933_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jmoldx.2018.08.002","article-title":"Ultra-rapid reporting of GENomic targets (URGENTseq): clinical next-generation sequencing results within 48 hours of sample collection","volume":"21","author":"Patel","year":"2019","journal-title":"J Mol Diagn"},{"issue":"9","key":"10.1016\/j.humpath.2025.105933_bib21","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/s41379-018-0067-x","article-title":"MYC\/BCL2\/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC\/BCL2 and MYC\/BCL6 double hit lymphomas","volume":"31","author":"Huang","year":"2018","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.humpath.2025.105933_bib22","doi-asserted-by":"crossref","first-page":"e815","DOI":"10.1016\/j.clml.2022.04.009","article-title":"Leukemic high grade B cell lymphoma is associated with MYC translocation, double hit\/triple hit status, transformation, and CNS disease risk: the Mayo clinic experience","volume":"22","author":"Kuhlman","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1016\/j.humpath.2025.105933_bib23","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.3109\/10428194.2016.1143939","article-title":"Double- and triple-hit lymphomas can present with features suggestive of immaturity, including TdT expression, and create diagnostic challenges","volume":"57","author":"Moench","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.humpath.2025.105933_bib24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.14740\/jh818","article-title":"MYC-positive diffuse large B-cell lymphoma in leukemic phase at presentation: a diagnostic and therapeutic challenge","volume":"10","author":"Bilgin","year":"2021","journal-title":"J Hematol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105933_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12308-019-00342-2","article-title":"Leukemic presentation of high-grade B cell lymphoma with MYC and BCL2 rearrangement\u2014a series of two cases and review of literature","volume":"12","author":"Shahid","year":"2019","journal-title":"J Hematopathol"},{"issue":"8","key":"10.1016\/j.humpath.2025.105933_bib26","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood-2013-11-540658","article-title":"A leukemic presentation of a \"triple-hit\" lymphoma","volume":"123","author":"Chen","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.humpath.2025.105933_bib27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/ejh.12397","article-title":"Double-hit lymphoma mimicking acute lymphoblastic leukemia at presentation","volume":"94","author":"Rashidi","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.humpath.2025.105933_bib28","first-page":"4","article-title":"Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphomaJ Hematol","volume":"18","author":"Chowdhury","year":"2025","journal-title":"Oncol"},{"issue":"5","key":"10.1016\/j.humpath.2025.105933_bib29","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1365-2141.2012.09209.x","article-title":"Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase","volume":"158","author":"Muringampurath-John","year":"2012","journal-title":"Br J Haematol"},{"issue":"25","key":"10.1016\/j.humpath.2025.105933_bib30","doi-asserted-by":"crossref","first-page":"38122","DOI":"10.18632\/oncotarget.9473","article-title":"Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC\/BCL2 double hit lymphoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.humpath.2025.105933_bib31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41379-021-00909-4","article-title":"Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge","volume":"35","author":"Khanlari","year":"2022","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105933_bib32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.pathol.2019.09.008","article-title":"High-grade B-cell lymphoma: a term re-purposed in the revised WHO classification","volume":"52","author":"Ok","year":"2020","journal-title":"Pathology"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725002205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725002205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T17:54:44Z","timestamp":1759859684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817725002205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":32,"alternative-id":["S0046817725002205"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2025.105933","relation":{},"ISSN":["0046-8177"],"issn-type":[{"type":"print","value":"0046-8177"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leukemic phase of MYC\/BCL2 double-hit high-grade B-cell lymphoma: A report of 35 cases","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2025.105933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105933"}}